Online Symptom Questionnaires for Older Adults With Acute Leukemia
Tests online questionnaires on how patients feel, in older adults with acute leukemia.
Plain-language title generated from the registry record
Registry title: Digital Patient-Reported Assessment in Older Adults With Acute Leukemia
Key facts
- Where
- Oviedo, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 65 or older with acute leukemia who are followed as outpatients at one hospital in Oviedo, Spain. They fill in health questionnaires on a digital device.
- Age
- 65 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed acute leukemia of myeloid or lymphoid origin, in active outpatient follow-up in the Hematology Service
Main reasons for not taking part
- Memory or thinking problems that stop you from understanding the questionnaires or answering them yourself, even with a caregiver's practical help
- A health condition that, in the treating hematologist's judgment, prevents completing the study steps
- Cannot access or use the MiAsturSalud/SESPA platform even with reasonable technical help
Read by machine on 12 November 2026.
Where in Spain
- Hospital Universitario Central de Asturias (HUCA)Oviedo, SpainContact: Hospital Universitario Central de Asturias (HUCA)No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundación para la Investigación Biosanitaria del Principado de Asturias
- Trial code
- NCT07597590
- Record updated
- 7 October 2026
- Original description
This pilot study will evaluate the feasibility of implementing a structured digital patient-reported assessment pathway in adults aged 65 years or older with acute leukemia at Hospital Universitario Central de Asturias, Oviedo, Spain. Participants will complete the EORTC QLQ-C30 and FACT-Leu remotely after the baseline visit and repeat the digital assessment 8-12 weeks after individual activation of the MiAsturSalud/SESPA digital pathway. The primary outcome will be the proportion of participants answering at least 80% of the items in the baseline digital questionnaire battery within 7 days after the baseline visit. Secondary outcomes will be caregiver assistance requirement, non-completion of the planned digital follow-up assessment, and elapsed baseline questionnaire completion time. During this feasibility study, participants will not concurrently receive the broader project's home-monitoring and clinical-alert intervention. The questionnaire pathway will not generate automated clinical alerts. Usual clinical care will continue. The study is not designed to establish clinical efficacy.Read full original descriptionShow less
Feasibility of a Structured Digital Patient-Reported Assessment Pathway in Older Adults With Acute Leukemia: A Prospective Single-Center Pilot Study
This pilot study will evaluate the feasibility of implementing a structured digital patient-reported assessment pathway in adults aged 65 years or older with acute leukemia at Hospital Universitario Central de Asturias, Oviedo, Spain. Participants will complete the EORTC QLQ-C30 and FACT-Leu remotely after the baseline visit and repeat the digital assessment 8-12 weeks after individual activation of the MiAsturSalud/SESPA digital pathway. The primary outcome will be the proportion of participants answering at least 80% of the items in the baseline digital questionnaire battery within 7 days after the baseline visit. Secondary outcomes will be caregiver assistance requirement, non-completion of the planned digital follow-up assessment, and elapsed baseline questionnaire completion time. During this feasibility study, participants will not concurrently receive the broader project's home-monitoring and clinical-alert intervention. The questionnaire pathway will not generate automated clinical alerts. Usual clinical care will continue. The study is not designed to establish clinical efficacy.
Inclusion: Age 65 years or older; Confirmed diagnosis of acute leukemia of myeloid or lymphoid origin; Active ambulatory follow-up in the Hematology Service at Hospital Universitario Central de Asturias; Ability to understand the questionnaires and provide their own responses, independently or with practical assistance from a caregiver; Access to a compatible internet-enabled digital device, either personally or through a caregiver; Provision of written informed consent.
Exclusion: Cognitive impairment that, in the treating hematologist's clinical judgment, prevents the participant from understanding the questionnaires or providing their own responses, despite permitted practical assistance from a caregiver; Clinical condition that, in the treating hematologist's judgment, precludes completion of the study procedures; Persistent inability to access or use the MiAsturSalud/SESPA platform despite reasonable technical support.